Best Pharma Stocks in November 2025 - Neuland Labs, Wockhardt & More – 5yr CAGR Basis

India’s pharmaceutical industry is projected to grow at a CAGR of over 10%, reaching around US$130 billion by 2030. The country has the highest number of USFDA-approved manufacturing facilities worldwide and is home to nearly 500 API manufacturers, contributing about 8% to the global API market. In this article, check the best pharma stocks in November 2025, based on the 5yr CAGR. 

Best Pharma Stocks in November 2025 – 5yr CAGR Basis

Note: The best pharma stocks listed here are as of Oct 28, 2025. The stocks are from Nifty 500 universe, with positive 1-yr returns. Sorted based on 5yr CAGR. 

Overview of the Best Pharma Stocks in November 2025 

1. Neuland Laboratories Ltd 

Neuland Laboratories is involved in the production and sale of active pharmaceutical ingredients (APIs), serving both Indian and global markets.

The company recorded a total income of ₹300.6 crore in Q1 FY26, marking a 32.4% year-on-year decline from ₹444.4 crore in Q1 FY25. Its Profit After Tax (PAT) dropped 86.1% YoY to ₹13.7 crore, compared to ₹98.3 crore in the corresponding quarter of the previous year.

Key Metrics: 

• Return on Capital Employed (ROCE): 20.69%
• Return on equity (ROE): 18.53%

2. Wockhardt Ltd 

Wockhardt is a global pharmaceutical and biotechnology company that is involved in the manufacturing of finished dosage formulations, injectables, biopharmaceuticals, as well as oral and topical products. For Q1 FY26, the company posted revenue of ₹738 crore, slightly lower than ₹747 crore in the same quarter last year. EBITDA for Q1 FY26 rose to ₹101 crore, marking a 1% qoq growth compared to ₹100 crore in the previous year.

Key metrics: 

• ROCE: 3.93%
• ROE: -1.13%

3. Caplin Point Laboratories Ltd 

Caplin Point Laboratories Ltd is into producing and sourcing Active Pharmaceutical Ingredients (APIs) and finished dosage formulations. The company is also active in research and development (R&D) and clinical trials.

In Q1 FY26, the total revenue grew 11.7% YoY to ₹533.36 crore compared to ₹477.52 crore in Q1 FY25. PAT also grew by 20.7%, reaching ₹150.76 crore against ₹124.92 crore in the same period last year.

Key metrics: 

• ROCE: 23.34%
• ROE: 20.50%

4. Glenmark Pharmaceuticals Ltd 

Glenmark Pharmaceuticals is a research-driven global pharmaceutical company operating across generics, specialty, and OTC segments, with a presence in over 80 countries. For Q1 FY26, the company posted revenues from operations of ₹32,644 million, a slight increase of 0.6% year-on-year from ₹32,442 million in Q1 FY25. However, the PAT dropped to ₹470 million compared to ₹3,402 million in the same period last year.

Key metrics: 

• ROCE: 16.02%
• ROE: 12.54%

5. Eris Lifesciences Ltd

Eris Lifesciences is involved in the manufacturing and marketing of pharmaceutical products. In Q1 FY26, the company reported revenue of ₹773 crore, reflecting a 7.4% year-on-year growth. The company’s PAT stood at ₹125 crore, marking a strong YoY increase of 41%.

Key metrics: 

• ROCE: 13.43%
• ROE: 10.84%

Also Read: Best Paint Stocks in Nov 2025!

Conclusion

The pharmaceutical industry remains a key contributor to India’s economic growth, driven by robust domestic demand, global expansion, and innovation. However, investors should stay aware of regulatory changes, pricing challenges, and competitive pressures.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.